Summary: We used time-updated Glasgow coma score and plasma sodium measurements, together with baseline patient characteristics, in a model to dynamically predict death in adults with tuberculous meningitis. Predictions can be made from any time point until day 30 of follow-up. 
Introduction
Tuberculous meningitis (TBM) is now one of the commonest causes of life-threatening meningitis worldwide, a distinction driven by the continued ability of Mycobacterium tuberculosis to evade global control efforts, the strong link between human immunodeficiency virus (HIV) infection and TBM, and the success of vaccination programmes against other bacterial causes of meningitis [1] . Despite the best available anti-tuberculosis drug treatment, death occurs in around 20% of HIV-uninfected and 40% of HIV-infected patients [2, 3] . Survivors are often left with irreversible neurological sequelae, which severely affects their quality of life [4] .
The pre-treatment predictors of poor outcome from TBM are well-studied. The British Medical Research Council (MRC) score to grade TBM severity has been used since 1948. Although it was defined empirically, rather than by statistical derivation, it has repeatedly been shown to be a good pretreatment predictor of death from TBM [5] [6] [7] [8] . It combines information on the patient's conscious state, assessed since 1974 by the Glasgow Coma Score (GCS) [5] , and focal neurological deficits. More recently, statistical modelling of data from large cohorts of patients with TBM have revealed other strong predictors of death, including HIV infection, older age, multi-drug resistance, and low numbers of cerebrospinal fluid (CSF) white cells [6, [8] [9] [10] . Indeed, we recently built and validated models for 9 month-mortality using a pooled database from five randomized controlled trials (RCT) and one observational study on TBM [8] . The models were based on several pre-treatment clinical variables and better predicted subsequent death than the MRC grade alone.
TBM requires 9-12 months of anti-tuberculosis drug treatment, during which complications from both the disease and the drugs can occur [2] . These complications change the likelihood of a poor outcome from TBM, but are not captured by current prognostic models based on pre-treatment variables alone.
Currently, there are no published models that take into account changing clinical variables after the start Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz262/5427068 by guest on 02 May 2019 of TBM treatment. Therefore, our aim was to develop and validate dynamic prediction models that incorporate baseline patient characteristics, as well as follow-up measurements (time-updated values) of GCS and plasma sodium. Our models were constructed using a large sample of 1048 Vietnamese adults with TBM. During the first 30 days of anti-tuberculosis treatment, we used updated information to predict mortality within the first 120 days. This time range of 30 days was selected based on our clinical experience that the first 30 days are critical to outcome. Most patients are hospitalised during this period and repeated measures of GCS and plasma sodium are usually available. We compared the predictive performance of these dynamic models to the previously published baseline models [8] .
Methods

Study population
We used data from three RCTs [3,11,12] and one observational study [13] on TBM which provided longitudinal information of GCS and plasma sodium during follow-up. The studies were conducted between 2004 and 2016 at Pham Ngoc Thach Hospital and the Hospital for Tropical Diseases, which are two tertiary referral hospitals in southern Vietnam. Patients were included in the studies if they were clinically diagnosed with TBM, defined as having more than 5 days of meningitis symptoms and CSF abnormalities. TBM diagnosis was categorised in all study participants as definite, probable, and possible. These diagnostic categories were defined by study-specific criteria in all patients enrolled before 2010 and by published consensus criteria from 2010 onwards [14] . A summary of the studies and their inclusion criteria is provided in supplementary Table S1 . The laboratory investigations and antituberculosis and adjunctive treatment are described in detail elsewhere [8] . The management of low or high plasma sodium was not standardised in any of the studies, but left to the individual practice of the attending physician. Study participants were excluded if no information on GCS or plasma sodium was available, if any of the baseline risk factors were missing, if an alternative diagnosis to TBM was 
Primary outcome
The primary outcome for this study was defined as overall mortality during 120 days from the start of anti-tuberculosis treatment. Follow-up was restricted to 120 days because deaths occurring within this period are much more likely to be attributable to TBM rather than an alternative cause. Since antituberculosis treatment usually started immediately following TBM diagnosis, time since TBM diagnosis and time since the initiation of anti-tuberculosis treatment can be seen to refer to the same time point in our analysis.
Predictors
As in our previous prognostic modelling study [8] , we constructed separate prediction models for HIVuninfected and HIV-infected patients. Our new models included both baseline patient characteristics and the longitudinal measurements of GCS and plasma sodium. We chose GCS and plasma sodium because both have been shown to be good pre-treatment predictors of death from TBM and both are monitored regularly in almost all settings. In the first 30 days of follow-up, most patients had daily GCS measurements in one trial [3] and weekly in the other studies. Plasma sodium was mostly measured daily for patients in one trial [12] and weekly in the other studies. We did not include other biomarkers such as CSF protein or ratio of CSF to blood glucose because on average we only had two measurements per patient in the first 30 days, precluding the development of a robust model.
We included the baseline characteristics that were identified as predictors of death within 9 months in our previous publication [8] . Specifically, in the HIV-uninfected population, these were age, history of previous TB treatment, MRC grade, focal neurological signs, and CSF lymphocyte count. In the HIV-infected population, these were weight, MRC grade, CSF lymphocyte count, study cohort, and peripheral blood CD4 cell count. Baseline laboratory values were defined as values recorded closest to enrolment (up to ±7 days from enrolment) [8] . Compared to the previous analysis, we excluded patients enrolled in two studies [15, 16] because their GCS and plasma sodium after the start of anti-tuberculosis treatment were not available. However, we retained the study cohort variable in the model for HIV-infected patients to account for improvements in treatment and patient supportive care over the last 15 years in Vietnam. The most significant of these was the nation-wide scale-up of free HIV antiretroviral therapy since 2005 [17] . We included sodium in the model for both populations, and used it as a time-updated instead of as a baseline variable.
Statistical analysis
The details of the statistical analysis are given in the Supplementary appendix S1. In brief, we used a mixed model landmark approach [18, 19] . We constructed a prediction model at a range of landmark time points: from day 0 to day 30 after diagnosis. For each landmark time, we created a data set including all patients who were still alive up to that landmark time point. For GCS, we used the last available measured value up till 10 days prior to the landmark time. With plasma sodium, we used the fitted value at the landmark time obtained from a linear mixed-effects model as explained in the appendix. To obtain predictions over a range of different time points using a single model, we implemented the "landmarking super model" approach [20] . Specifically, we combined the 31 landmark data sets, one for each day since initiation of anti-tuberculosis treatment until day 30. The stacked data was analysed using a Cox proportional hazards model with landmark time included as a stratification factor. We allowed for a non-linear relation between sodium and mortality that can vary over time.
Other predictors were included linearly. We also explored a number of extra analyses and an alternative modelling approach, which are described in the Supplementary appendix S1.
We assessed the discrimination and calibration ability of the models based on the area under the receiver operating characteristic curve (AUC), the Brier score (i.e. the prediction error with a square loss function) [18] , and the calibration plot [21] . A higher AUC value and a lower Brier score indicate better performance. The evaluation was carried out at day 10, 20 and 30 for mortality until day 60, 90 and 120 after diagnosis. We also calculated the AUC and Brier score of the published baseline model [8] at the same prediction times using our landmark data sets. We used bootstrap internal validation to correct for the over-optimism in the predictive performance [22] . The final models have been implemented in a web-based calculator to facilitate their application in clinical practice. All analyses were conducted using R software, version 3.5.0 [23] .
Results
Baseline characteristics of study participants
In total, there were 1248 patients in the four studies, of which 1068 were included in the analysis. The reasons for excluding the other 180 patients were: confirmed other diagnosis (n = 16), first-line antituberculosis drugs not received (n = 3), missing information on either of the two markers (n = 7), missing values for at least one of the baseline patient characteristics (n = 154). Baseline characteristics of the included patients are given in Table 1 . 550 (51%) were HIV-uninfected, and 518 (49%) were HIV-infected. Table 2 gives parameter estimates of the dynamic landmark supermodels. Regarding GCS, a higher value indicated lower mortality with a hazard ratio of 0.76 (95% confidence interval (CI): 0.71-0.81) and 0.85 (95% CI: 0.81-0.91) in HIV-uninfected and HIV-infected patients respectively. Figure 2 displays the hazard ratio for sodium at day 0, 10 and 30. Sodium concentrations of 135 mmol/L were taken as the reference. As can be seen, the association between plasma sodium and mortality differed by HIV status.
Parameter estimates
In HIV-uninfected patients, it was heterogeneous over time. Higher sodium concentrations were associated with worse prognosis from baseline until day 10 of treatment. However, by day 30, higher sodium concentrations were associated with increased survival. In HIV-infected patients, higher sodium concentrations uniformly associated with better prognosis across all prediction time points.
Compared with the published baseline model [8] , the strength of the association between MRC grade and mortality was attenuated with the inclusion of time-updated GCS. This is not surprising as GCS is strongly correlated with MRC grade. The strength of the association for the other baseline covariates was similar between the dynamic models and the baseline models, except for history of previous TB treatment in the model for HIV-uninfected patients. The hazard ratio for this predictor was 0.57 indicating a beneficial effect which contradicted with that in the baseline model (HR = 1.57, CI 1.09 -2.26). However, it was not statistically significant at 0.05 level (p-value = 0.27, CI 0.21-1.54).
Predictive performance
All the considered alternative analyses (Supplementary appendix S1) did not improve the predictive performance of the models. in HIV-infected subjects. In terms of calibration, Figure S2 shows good agreement between the predicted risks and the observed risks for all three chosen landmark time points. Overall performance, as measured by the Brier score, was also improved in the dynamic models compared to the baseline models (Table S2) .
Model display and illustration
We implemented the models in a user-friendly web-based calculator, which is available at: https://thaole.shinyapps.io/DynamicTBMApp/. The web calculator allows the user to make predictions of mortality within 120 days after the initiation of TB treatment from any of the first 30 days. As in the baseline model's web calculator for HIV-infected patients (https://thaole.shinyapps.io/TBMApp/), we chose the intensified trial [3] as cohort variable because it is the most recent cohort.
In Figure 3 , we illustrate the use of the model to dynamically predict mortality until day 120 for a 39 years old HIV-uninfected patient without previous TB, having MRC grade III, no focal neurological signs at enrolment and with CSF lymphocyte count at baseline of 73.5 cells/μL (patient A). A similar illustration for an HIV-infected patient (patient B) is in Supplementary Figure S3 . Baseline characteristics of the two patients are documented in Supplementary Table S3 . As can be seen, the predicted survival probability is updated as new information on GCS and plasma sodium becomes available. Of note, the risk predictions can vary substantially over the landmark days, indicating the importance of updating prediction using the most recent information.
Discussion
Using most recent information on disease state is important for monitoring patients, tailoring treatment and improving disease outcomes. We developed and validated a dynamic prediction model for death in TBM patients with and without HIV coinfection. The models used time-updated information on Glasgow coma score and plasma sodium as well as baseline patient characteristics. Indeed, our model provided better predictive performance than the model that only used baseline characteristics [8].
Our model confirmed that GCS is a strong predictor of outcome in both populations. Regarding plasma sodium, hyponatraemia is a common complication of TBM, usually caused by cerebral salt wasting or the syndrome of inappropriate anti-diuretic hormone [7] . Its impact upon survival has not been wellstudied, although low sodium concentrations can cause reduced consciousness and exacerbate raised intracranial pressure. Mostly, higher sodium concentrations during treatment indicated better outcome. While this association was uniformly observed over the first 30 days of treatment in HIVinfected patients, in HIV-uninfected patients higher concentration predicted worse outcomes in the first 10 days of treatment, and switched to predicting better outcomes thereafter (Figure 2 ). This is an intriguing finding which is not easily explained. Possible explanation may be the contribution of 12 neurogenic diabetes insipidus, which occurs in severe disease affecting the hypothalamic-pituitary access [24] , and can cause harmful hypernatraemia. It is unclear why HIV-infection may drive these differences and the findings increase the importance of better understanding and managing disorders of sodium homeostasis associated with TBM.
In our database, there are seven HIV-uninfected patients and eight HIV-infected patients with at least one measurement of plasma sodium higher than 145 mmol/L (hypernatraemia) in the first 30 days. Of those, seven patients died (four in HIV-uninfected and three in HIV-infected patients). All of these deaths happened very early, within the first 25 days since the start of anti-tuberculosis treatment. Due to the low number of hypernatraemia cases and the timing of the events, the impact of high sodium values on mortality was not captured thoroughly in our model, especially at later landmark times.
Our study has several limitations. First, we only considered GCS and plasma sodium as time-updated markers. Including other markers could potentially improve the model predictive performance. In order to include them in future studies, they should be collected more frequently over time. Second, the models were developed and validated using data solely from two recruiting centres in the South of Vietnam. This restriction may affect the generalisability of the models. Thus, the models require validation in different patient populations.
In conclusion, our dynamic prediction models allowed us to predict 120-day mortality from TBM using time-updated data from the first 30 days of treatment. The models were carefully constructed and validated internally based on a large data set of 1048 patients. To the best of our knowledge, they are the first published dynamic prediction models for TBM. We hope that they will be validated in other patient populations and prove useful in practice by providing clinicians and patients better information and facilitate decision making regarding treatment and patient management. 
